All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @iamalmaramirez on TikTok · 73s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @iamalmaramirez's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00It's shot day and I want to give you an update of how I'm looking and how many
  2. 0:03pounds I've lost officially 13 pounds. I weighed myself this morning. This will even
  3. 0:12look like I had a baby eight weeks ago. Tricepotet is definitely helping. My
  4. 0:19start with was 181. I am 176. That's 13 pounds right? And my weight goal is 145 to
  5. 0:31150. I get the medication from IVRX is a pharmacy. I really like it because it
  6. 0:37gets delivered to your home and it's ordered by their own doctor. And if you
  7. 0:41are already interested at the time it's very cost-effective, they can continue on
  8. 0:47your dose. I like to do my arm because I've heard that it gets to your system
  9. 0:53faster or like more efficiently instead of the leg or your stomach.
  10. 0:59Tryin' them how skinny I am. Hi.

TikTok's postpartum GLP-1 claims need more context

Alma Ramirez

TikTok creator

21.0K viewsWatch on TikTok

Quick answer

The creator is using tirzepatide, a dual GIP/GLP-1 receptor agonist, approximately eight weeks postpartum, sourced from a compounding pharmacy. She reports weight loss but presents internally inconsistent numbers (5-pound measured difference vs. claimed 13 pounds), and her injection site preference claim lacks support in tirzepatide pharmacokinetic data. Postpartum use raises unresolved safety questions, particularly around breastfeeding, as the drug's lactation profile has not been established in clinical trials.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TikTok's postpartum GLP-1 claims need more context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

TikTok's postpartum GLP-1 claims need more context is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "TikTok's postpartum GLP-1 claims need more context" from Alma Ramirez. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is using tirzepatide, a dual GIP/GLP-1 receptor agonist, approximately eight weeks postpartum, sourced from a compounding pharmacy.

The reason this review is not generic is the source wording and the canonical claim label "glp1 in bio for more info someone told me is the easy way out." In this clip, the useful excerpt is: "It's shot day and I want to give you an update of how I'm looking and how many pounds I've lost officially 13 pounds." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The creator's own numbers contradict her 13-pound loss claim: 181 minus 176 equals 5 pounds, not 13.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is using tirzepatide, a dual GIP/GLP-1 receptor agonist, approximately eight weeks postpartum, sourced from a compounding pharmacy.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is using tirzepatide, a dual GIP/GLP-1 receptor agonist, approximately eight weeks postpartum, sourced from a compounding pharmacy. She reports weight loss but presents internally inconsistent numbers (5-pound measured difference vs. claimed 13 pounds), and her injection site preference claim lacks support in tirzepatide pharmacokinetic data. Postpartum use raises unresolved safety questions, particularly around breastfeeding, as the drug's lactation profile has not been established in clinical trials.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produced roughly 20.9% mean weight loss at 15 mg over 72 weeks, but this trial excluded postpartum and breastfeeding participants.
  • The creator's own numbers contradict her 13-pound loss claim: 181 minus 176 equals 5 pounds, not 13.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produced roughly 20.9% mean weight loss at 15 mg over 72 weeks, but this trial excluded postpartum and breastfeeding participants.
  • The creator's own numbers contradict her 13-pound loss claim: 181 minus 176 equals 5 pounds, not 13.
  • FDA-approved tirzepatide prescribing information lists abdomen, thigh, and upper arm as interchangeable injection sites with no pharmacokinetic advantage attributed to the arm.
  • Compounded tirzepatide is not FDA-approved and has not been evaluated for bioequivalence to Zepbound or Mounjaro. The FDA issued explicit 2024 warnings about compounded GLP-1 products.
  • Tirzepatide's safety during breastfeeding has not been established. The drug label states no data exists on its presence in human milk or effects on the nursing infant.
  • ACOG recommends conservative approaches to postpartum weight loss interventions, particularly when breastfeeding, and any GLP-1 use at 8 weeks postpartum warrants direct OB-GYN involvement.
  • The #ivyaffiliate and #ivypartner hashtags indicate this is sponsored content, which does not disqualify the experience but does mean the creator has a financial relationship with the pharmacy being recommended.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @iamalmaramirez actually say?

The creator posted a "shot day" update, reporting she lost 13 pounds since starting tirzepatide eight weeks after giving birth. She said her starting weight was 181 pounds, her current weight is 176 pounds, and her goal is 145 to 150 pounds. She also said she gets her medication from a compounding pharmacy called IVRX, which delivers to her home and uses its own prescribing doctor. One specific claim stood out: she said she injects in the arm because it gets the drug to her system "faster or more efficiently" than the leg or stomach.

There is also a math problem here that nobody seemed to catch. If she started at 181 and is now at 176, that is a 5-pound difference, not 13 pounds. She stated both numbers in the same video. At least one of them is wrong, and that discrepancy matters when someone is watching this as a weight-loss reference.

Does the science back this up?

Tirzepatide is a dual GIP/GLP-1 receptor agonist, and the clinical evidence for weight loss is genuinely strong. However, postpartum use introduces real variables that the research has not fully addressed.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15 mg produced a mean weight reduction of about 20.9% over 72 weeks in adults with obesity. That is a serious effect size. But SURMOUNT-1 excluded breastfeeding individuals, and the creator did not clarify whether she is nursing. That matters because tirzepatide's safety profile during lactation is not established. The FDA label explicitly notes that data on use while breastfeeding is absent.

Eight weeks postpartum is also early. The American College of Obstetricians and Gynecologists recommends waiting until at least six weeks postpartum before initiating weight-loss interventions, and even then, the guidance is conservative when breastfeeding is involved. None of this makes her experience invalid, but the context she left out is clinically relevant.

What did they get wrong (or right)?

The injection site claim is where the science gets interesting, and not in the creator's favor. She said the arm gets tirzepatide to the system "faster or more efficiently." There is limited pharmacokinetic data specifically on tirzepatide injection site differences. What exists for GLP-1 class drugs more broadly, including semaglutide studies, does not consistently show the arm to be meaningfully superior in bioavailability compared to the abdomen or thigh. The prescribing information for Mounjaro and Zepbound lists the abdomen, thigh, and upper arm as interchangeable sites with no stated preference. This claim appears to be anecdote or gym-culture lore, not pharmacology.

What she got right: framing medication-assisted weight loss as "not the easy way out" is fair. The SURMOUNT clinical data makes clear that tirzepatide works alongside significant metabolic and behavioral changes, not instead of them. Reducing stigma around GLP-1 use is a legitimate public health goal.

The math error is a real credibility problem. If you are going to post a weight update, the numbers need to be consistent.

What should you actually know?

A few things deserve direct attention if you are considering something similar after this video.

  • Compounded tirzepatide is not the same as FDA-approved Zepbound or Mounjaro. Compounded versions are not evaluated by the FDA for safety, purity, or efficacy. The FDA has warned consumers about this repeatedly, including in 2024 guidance on compounded GLP-1 products. "Cost-effective" does not mean equivalent.
  • Postpartum metabolic recovery is its own process. Weight loss in the first few months after birth involves hormonal shifts, fluid changes, and, if breastfeeding, additional caloric demands. Attributing all change to tirzepatide this early is not reliable signal.
  • The arm injection claim is not supported by tirzepatide prescribing data. Rotate sites as directed. Do not optimize based on TikTok tips.
  • If you are postpartum and interested in any GLP-1 medication, that conversation needs to happen with an OB-GYN or a physician who knows your full postpartum and lactation status, not just a telehealth intake form.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Alma Ramirez · TikTok creator

21.0K views on this video

🔗in bio for more info Someone told me is the easy way out, but it’s not. Leverage science to your favor ✨ #ivyaffiliate #ivypartner @IVY #postpartumjourney #postpartumweightloss

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide produced roughly?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide produced roughly 20.9% mean weight loss at 15 mg over 72 weeks, but this trial excluded postpartum and breastfeeding participants.

What does the video say about the creator's own numbers contradict her 13-pound loss claim: 181?

The creator's own numbers contradict her 13-pound loss claim: 181 minus 176 equals 5 pounds, not 13.

What does the video say about fda-approved tirzepatide prescribing information lists abdomen, thigh,?

FDA-approved tirzepatide prescribing information lists abdomen, thigh, and upper arm as interchangeable injection sites with no pharmacokinetic advantage attributed to the arm.

What does the video say about compounded tirzepatide?

Compounded tirzepatide is not FDA-approved and has not been evaluated for bioequivalence to Zepbound or Mounjaro. The FDA issued explicit 2024 warnings about compounded GLP-1 products.

What does the video say about tirzepatide's safety during breastfeeding has not been established. the drug?

Tirzepatide's safety during breastfeeding has not been established. The drug label states no data exists on its presence in human milk or effects on the nursing infant.

What does the video say about acog recommends conservative approaches to postpartum weight loss interventions, particularly?

ACOG recommends conservative approaches to postpartum weight loss interventions, particularly when breastfeeding, and any GLP-1 use at 8 weeks postpartum warrants direct OB-GYN involvement.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Alma Ramirez, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.